WNK lysine deficient protein kinase 4Genealiases: PHA2B · PRKWNK4
Q-omics provides the consensus-scored WNK4 profile across patient tissues and cancer cell-line models. WNK4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, WNK4 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, WNK4 RNA expression shows 17,374 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRC, and THYM as cancer lineages where WNK4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WNK4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WNK4 survival associations across molecular data types. WNK4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WNK4 RNA expression–survival associations across cancer types. High WNK4 expression shows unfavorable associations in ACC and LUAD, but favorable associations in UVM, BRCA, PAAD and KICH. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for WNK4 RNA expression.
This table summarizes WNK4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for WNK4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WNK4 shows lower tumor expression in KIRC, HNSC, KICH, KIRP and THCA and higher tumor expression in LIHC. The KIRC box plot shows higher WNK4 RNA expression in normal versus tumor tissue (log2 FC = −4.238, t-test p < 0.001).
This table shows molecular features associated with WNK4 in patient tissues and cancer cell lines. In patient samples, WNK4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, WNK4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
